Key statistics dashboard for BioVie Inc. (BIVI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
Stock Data
| Price | $1.72 |
| Market Cap | $13M |
| Beta | 0.56 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.54 |
| Price / Book | 1.26 |
| P/S | 0.00 |
| P/FCF | -0.68 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 3.59 |
| Quick Ratio | 3.59 |
| Cash Ratio | 2.37 |
| Debt / Equity | 0.03 |
| Debt / Assets | 1.93% |
| Interest Coverage | -1265.39 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -21.39 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.36 |
| Cash per share | 1.19 |
| FCF per share | -2.52 |
| Tangible Book Value per share | 1.32 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Related companies: ARTL · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of BIVI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks